Sight Sciences, Inc.'s share price has fallen by -13.3% in the past 3 weeks, despite reporting a narrower-than-expected net loss in Q1 and sticking to its 2023 guidance. Sight Sciences' key Q1 2023 ...
Evercore ISI analyst Vijay Kumar raised the firm’s price target on Exact Sciences (EXAS) to $70 from $60 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life ...
The average one-year price target for Wave Life Sciences (NasdaqGM:WVE) has been revised to $28.29 / share. This is a decrease of 20.34% from the prior estimate of $35.51 dated March 25, 2026. The ...
BTIG analyst Mark Massaro lowered the firm’s price target on Exact Sciences (EXAS) to $65 from $82 and keeps a Buy rating on the shares. The company delivered a Q3 revenue miss and large guide-down, ...
Piper Sandler analyst David Westenberg lowered the firm’s price target on Exact Sciences (EXAS) to $75 from $85 following quarterly results. The firm keeps an Overweight rating on the shares.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results